Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Low-grade inflammation in obesity is associated with accumulation of the macrophage-derived cytokine osteopontin (OPN) in adipose tissue and induction of local as well as systemic insulin resistance. Since glucose-dependent insulinotropic polypeptide (GIP) is a strong stimulator of adipogenesis and may play a role in the development of obesity, we explored whether GIP directly would stimulate OPN expression in adipose tissue and thereby induce insulin resistance. GIP stimulated OPN protein expression in a dose-dependent fashion in rat primary adipocytes. The level of OPN mRNA was higher in adipose tissue of obese individuals (0.13 ± 0.04 vs. 0.04 ± 0.01, P < 0.05) and correlated inversely with measures of insulin sensitivity (r = -0.24, P = 0.001). A common variant of the GIP receptor (GIPR) (rs10423928) gene was associated with a lower amount of the exon 9-containing isoform required for transmembrane activity. Carriers of the A allele with a reduced receptor function showed lower adipose tissue OPN mRNA levels and better insulin sensitivity. Together, these data suggest a role for GIP not only as an incretin hormone but also as a trigger of inflammation and insulin resistance in adipose tissue. Carriers of the GIPR rs10423928 A allele showed protective properties via reduced GIP effects. Identification of this unprecedented link between GIP and OPN in adipose tissue might open new avenues for therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was postulated that GIP might promote endothelin-1’s (ET-1) release from endothelial cells, thereby increasing human osteopontin levels.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [125]
In the citing paper
“Furthermore, increased levels of osteopontin (which is involved in T-cell activation and differentiation as well as macrophage activation) and a higher risk of CVD were linked to GIP-R polymorphisms and circulating levels of GIP [125].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Calculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“GIP stimulates adipose tissue formation independently of its effect on insulin secretion (5), and inactivation of the GIP receptor (GIPR) in adipose tissue has been suggested as a strategy to treat obesity (6).”
BackgroundPoulsen, P., Ohm Kyvik, K., Vaag, A., & Beck-Nielsen, H. (1999) · Diabetologia · doi:10.1007/s001250051131 · Cited by 618
Self-citationAdipose Tissue, Inflammation and Atherosclerosis
Gustafson, B. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3939 · Cited by 469
Nomiyama, T., Perez-Tilve, D., Ogawa, D., Gizard, F., Zhao, Y., Heywood, E. B., Jones, K. L., Kawamori, R., Cassis, L. A., Tschöp, M. H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31986 · Cited by 401
Pietiläinen, K. H., Naukkarinen, J., Rissanen, A., Saharinen, J., Ellonen, P., Keränen, H., Suomalainen, A., Götz, A., Suortti, T., Yki-Järvinen, H., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050051 · Cited by 303
Honnor, R. C., Dhillon, G. S., & Londos, C. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95711-x · Cited by 296
Neutralization of Osteopontin Inhibits Obesity-Induced Inflammation and Insulin Resistance
Kiefer, F. W., Zeyda, M., Gollinger, K., Pfau, B., Neuhofer, A., Weichhart, T., Säemann, M. D., Geyeregger, R., Schlederer, M., Kenner, L., et al. (2010) · Diabetes · doi:10.2337/db09-0404 · Cited by 200
Wang, J., Kuusisto, J., Vänttinen, M., Kuulasmaa, T., Lindström, J., Tuomilehto, J., Uusitupa, M., & Laakso, M. (2007) · Diabetologia · doi:10.1007/s00125-007-0656-6 · Cited by 178
Self-citation
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Molecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
The multiple functions and mechanisms of osteopontin
Icer, M. A., & Gezmen-Karadag, M. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.07.003 · Cited by 606
Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes
Kahles, F., Findeisen, H. M., & Bruemmer, D. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.03.004 · Cited by 408
Nilsson, E., Jansson, P. A., Perfilyev, A., Volkov, P., Pedersen, M., Svensson, M. K., Poulsen, P., Ribel-Madsen, R., Pedersen, N. L., Almgren, P., et al. (2014) · Diabetes · doi:10.2337/db13-1459 · Cited by 391
Self-citation
Metadata
- Authors
- Ahlqvist, E., Osmark, P., Kuulasmaa, T., Pilgaard, K., Omar, B., Brøns, C., Kotova, O., Zetterqvist, A. V., Stančáková, A., Jonsson, A., Hansson, O., Kuusisto, J., Kieffer, T. J., Tuomi, T., Isomaa, B., Madsbad, S., Gomez, M. F., Poulsen, P., Laakso, M., Degerman, E., Pihlajamäki, J., Wierup, N., Vaag, A., Groop, L., & Lyssenko, V.
- Affiliations
- Lund University (SE)
- University of Eastern Finland (FI)
- Steno Diabetes Center, Gentofte, Denmark
- University of British Columbia (CA)
- Folkhalsan Research Centre, Helsinki, Finland
- Folkhälsans Forskningscentrum (FI)
- University of Copenhagen (DK)
- University of Helsinki (FI)
- Corresponding author
- Lyssenko, Valeriya
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-05-17
- Volume
- 62
- Issue
- 6
- Pages
- 2088-2094
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3661641
- OpenAlex
- W2159566085
- Cited by
- 96
- References
- 20
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 14 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 12 · 2014: 8 · 2013: 6
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Lunds Universitet
- Novo Nordisk Fonden (NNF12OC1016467)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- glucose-dependent insulinotropic polypeptide, osteopontin, insulin resistance, adipose tissue, obesity, low-grade inflammation, GIP receptor, adipocytes, incretins, adipogenesis, insulin sensitivity
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Aged, Alleles, Animals, Cells, Cultured, Female, Gastric Inhibitory Polypeptide, Humans, Insulin Resistance, Male, Middle Aged, Receptors, Gastrointestinal Hormone, Mice, Rats, Osteopontin, Young Adult, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.